Current Pharmaceutical Design - Volume 19, Issue 35, 2013

The conversion of drugs into drug nanoparticles (nano-drugs) represents a feasible method to enhance bioavailability of otherwise sparingly soluble-drugs. Nano-drugs enhance bioavailability through the improvement of dissolution rate and saturation solubility of drugs, by virtue of their small sizes. Nano-drugs available in the market are usually produced by top-down methods, such as wet milling and high pressure homogenization. These conventional top-down methods, however, suffer from high energy and time requirement, as well as wide and inconsistent nano-drug size distribution. Furthermore, commercially available nano-drugs are predominantly crystalline while amorphous nano-drugs are largely neglected despite their propensity to generate high saturation solubility. In this review, nonconventional methods to prepare crystalline and amorphous nano-drugs are discussed, with the bioavailability enhancing characteristics highlighted. Both top-down and bottom-up methods are covered, finally, a sustainability-based perspective comparing amorphous and crystalline nano-drugs is presented.

Nano-formulation of poorly water-soluble drugs has been developed to enhance drug dissolution. In this review, we introduce nano-milling technology described in recently published papers. Factors affecting the size of drug crystals are compared based on the preparation methods and drug and excipient types. A top-down approach using the comminution process is a method conventionally used to prepare crystalline drug nanoparticles. Wet milling using media is well studied and several wet-milled drug formulations are now on the market. Several trials on drug nanosuspension preparation using different apparatuses, materials, and conditions have been reported. Wet milling using a high-pressure homogenizer is another alternative to preparing production-scale drug nanosuspensions. Dry milling is a simple method of preparing a solid-state drug nano-formulation. The effect of size on the dissolution of a drug from nanoparticles is an area of fundamental research, but it is sometimes incorrectly evaluated. Here, we discuss evaluation procedures and the associated problems. Lastly, the importance of quality control, process optimization, and physicochemical characterization are briefly discussed.

The development of drug nanoparticles has attracted substantial attention because of their potential to improve the dissolution rate and oral availability of poorly water-soluble drugs. This review summarizes the recent articles that discussed nanoparticle-based oral drug delivery systems. The preparation methods were categorized as top-down and bottom-up methods, which are common methods for preparing drug nanoparticles. In addition, methods of handling drug nanoparticles (e.g., one-step preparation of nanocomposites which are microparticles containing drug nanoparticles) were introduced for the effective preservation of drug nanoparticles. The carrier-based preparation of drug nanoparticles was also introduced as a potentially promising oral drug delivery system.

Due to uniquely ordered nanoporous structure and high surface area as well as large pore volume, mesoporous materials have exhibited excellent performance in both controlled drug delivery with sustained release profiles and formulation of poorly aqueoussoluble drugs with enhanced bioavailability. Compared with other bulk excipients, mesoporous materials could achieve a higher loading of active ingredients and a tunable drug release profile, as the high surface density of surface hydroxyl groups offered versatility to be functionalized. With drug molecules stored in nano sized channels, the pore openings could be modified using functional polymers or nano-valves performing as stimuli-responsive release devices and the drug release could be triggered by environmental changes or other external effects. In particular, mesoporous silica nanoparticles (MSN) have attracted much attention for application in functional target drug delivery to the cancer cell. The smart nano-vehicles for drug delivery have showed obvious improvements in the therapeutic efficacy for tumor suppression as compared with conventional sustained release systems, although further progress is still needed for eventual clinical applications. Alternatively, unmodified mesoporous silica also exhibited feasible application for direct formulation of poorly water-soluble drugs to enhance dissolution rate, solubility and thus increase the bioavailability after administration. In summary, mesoporous materials offer great versatility that can be used both for on-demand oral and local drug delivery, and scientists are making great efforts to design and fabricate innovative drug delivery systems based on mesoporous drug carriers.

Some kinds of amphiphilic lipids can spontaneously self-assemble with a proper ratio of water to form liquid crystalline, also known as cubic phase. With a curved bi-continuous lipid bilayer and two congruent networks of water channels, cubic phases can enclose hydrophilic, amphiphilic and hydrophobic drugs for delivery. Nanostructured cubosomes, prepared by fragmentation of bulk cubic phase gels or lyotropic methods, retain the same inner structure of cubic phase and possess much larger specific surface area and lower viscosity. These unique properties make cubosomes excellent delivery systems applicable for oral, mucosal, transdermal and parenteral drug delivery. This article gave an overview of the accelerated development and current status of cubosomes research, with respect to their preparation, characteristics and applications in pharmaceutics.

Recent advances in the fabrication, characterization and application of micro- and nano-particles that possess a non-uniform internal structure are reviewed. The particle structures include core-shell particles, particles with multiple cores or a multi-layered structure, porous particles with both regular and random pore structure, as well as complex composite particles possessing several of the above features. Particles based on “hard” inorganic materials such as silica, “soft” organic materials such as polymers and their composites are considered. The fabrication approaches include bottom-up self-assembly techniques, templating methods, microfluidics, and various emulsion-based routes to structured micro- and nano-particle formation, combined with both physical (e.g. Pickering emulsions) and chemical (e.g. polymerization, precipitation) processes for the material deposition. The applications of the structured particles for the encapsulation and controlled delivery of active substances are then reviewed with emphasis on those systems where the complex particle structure can provide specific benefits such as in-situ formation of the active substance or precise control over the release profile. Likely future research directions and prospects are discussed.

Restenosis, the re-narrowing of a blood vessel after removal of atherosclerotic plaque, is a major limitation of surgical treatments for atherosclerosis. Various attempts to prevent or treat restenosis by pharmacological or mechanical approaches have had limited success in clinical trials. Hence, there is wide interest in developing new strategies to prevent or treat restenosis. This review discusses ‘a new-generation therapy’ that uses functional nanoparticles to effectively deliver active drug molecules. The potential platforms for nanoparticle-based solutions to restenosis include organic (e.g. polymers, liposomes, and proteins) and inorganic nanoparticles (e.g. layered double hydroxides, titanium oxide nanotubes, and magnetic nanoparticles,). Many in vitro and in vivo studies based on these platforms demonstrate the feasibility and potential of using nanoparticle drug delivery systems for preventing or treating restenosis, but as yet few have reached clinical trials. It is suggested that using inorganic nanoparticles to target deliver multi-functional drugs will be a promising approach to preventing or treating restenosis.

With the recent progress in biotechnology and genetic engineering, a variety of proteins have formed a very important class of therapeutic agents. However, most proteins have short half-lives in vivo requiring multiple treatments to provide efficacy. In order to overcome this limitation, sustained release systems as hydrophilic microspheres and hydrophobic microcapsules have received extensive attention in recent years. As therapeutic proteins delivery systems, it is necessary to maintain protein bioactivity during microspheres or microcapsules formation as much as possible. This paper reviews different influencing factors that are closely involved in protein denaturation during the preparation of hydrophilic polymer microspheres and hydrophobic polymer microcapsules. The various strategies usually employed for overcoming these obstacles are described in detail. Both processing and formulation parameters can be modified for improving protein stability. The maximum or full protein stability retention within the microspheres or microcapsules might be achieved by individual or combined optimized strategies. In addition, the common techniques for proteins stability determination are also briefly reviewed.

Exposure of human skin to nanoparticles (NPs) is increasing with the development of nanotechnology and new applications of NPs in medicine. Safety concerns have sparked debate on the capacity of NPs to penetrate through skin and enter into the body. This article attempts to summarize the recent evidence on whether NPs penetrate human skin and the factors that may affect the penetration. Skin structure and penetration mechanisms are reviewed to provide background information. Size, shape, formulation, surface properties and application methods and their effects on skin penetration are specifically discussed. Finally, the relationship between skin penetration and nanotoxicity is reviewed to further emphasise the importance of the research in this area.

Pregabalin is an anticonvulsant drug that binds to the α2δ(alpha2delta) subunit of the voltage-dependent calcium channel in central nervous system (CNS). Pregabalin decreases the release of neurotransmitters, including glutamate, norepinephrine, substance P and calcitonin gene-related peptide. Purpose of this paper is to offer a qualitative overview of the studies currently available in literature about this drug, examining the effectiveness of pregabalin in its various fields of application. Our analysis, conducted on a final selection of 349 scientific papers, shows that pregabalin may help to reduce pain in diabetic neuropathy, in post-herpetic neuralgia and in some patients affected by fibromyalgia. It is also effective for the treatment of diverse types of seizures and has similar efficacy to benzodiazepines and venlafaxine in anxiety disorder. Moreover, pregabalin may be a therapeutic agent for the treatment of alcohol abuse, in both withdrawal phase and relapse prevention. Possible implications in the treatment of benzodiazepines dependence are emerging, but a potential abuse or misuse of the drug has also been reported. Range of dosage may fluctuate considerably, from 75 mg to 600 mg per day. Further studies are needed to completely understand pregabalin mechanism of action in the different diseases.

Rheumatoid arthritis (RA) is a chronic inflammatory disease in which the progressive destruction of joint causes morbidity. It is also associated with an increased risk of atherosclerosis, which can result in cardiovascular disease and mortality. The therapeutic goal is to control the systemic inflammation to obtain not only the remission of symptoms, but also improve general state of health. Although recent biologic immunosuppressive therapies targeting pro-inflammatory cytokines have spawned a paradigm shift regarding the prognosis of RA, these therapies possess inherent side effects. Also, early diagnosis of the disease remains confounded by uncertainty. While the mechanisms responsible for the onset of RA remain unclear, reactive oxygen species (ROS) play a significant role in the pathogenesis of RA. ROS play a central role both upstream and downstream of NF-κB and TNFα pathways, which are located at the center of the inflammatory response. Among the ROS, the hydroxyl radical is the most harmful, and molecular hydrogen (H2) is a selective scavenger for this species. Recently, it has been shown that H2 is useful when administered along with the conventional therapy in RA as it acts to reduce oxidative stress in the patients. Especially in the early stage, H2 showed significant therapeutic potential, which also seemed to assist diagnosis and treatment decisions of RA. The possible expectations regarding the potential benefits of H2 by reducing the oxidative stress, resulting from inflammatory factors, are raised and discussed here. They include prevention of RA and related atherosclerosis, as well as therapeutic validity for RA.

Background: Abnormal expression of microRNAs (miRNAs) is closely related to glioma, which is one of the most common malignant brain tumors. The current study is to identify the key miRNAs involved in the pathogenesis of glioma and to discover novel therapeutic targets for this disease. Materials and Methods: Total RNA was extracted from glioma tissues of 100 patients. The microRNA microarray and the northern blot were used to detect the changes of miRNAs expression in 7 pairs of glioma specimens. Relative expressions of miR-23a were validated by real-time reverse transcription polymerase chain reaction (RT-PCR) with specific Taqman probes. In order to evaluate the role of miR-23a, the miR-23a mimics and anti-miR-23a oligonucleotides were transfected to glioma cell lines; the cell proliferation, apoptosis, cell cycle percentage, cell migration and invasion abilities were evaluated in vitro. The target genes of miR-23a were also investigated using the bioinformatics tools. The expression of the apoptotic protease activating factor-1 (APAF1), which might be one of the direct targets of miR-23a, was also analyzed using the luciferase reporter assay and western blot analysis in 293T cells and glioma cell line, respectively. Results: The microRNA microarray and the northern blot results showed that the expressions of miR-23a in glioma tissues were significantly upregulated. The miR-23a expression levels identified using real time RT-PCR in tumor tissues of 79 samples were higher than in the matched adjacent tissues. By transfection of anti-miR-23a oligonucleotide, the results showed that the proliferation, migration, and invasion of glioma cell lines were significantly suppressed. The bioinformatics searching results showed that APAF1 might be a direct target gene of miR-23a, and it was supported by the luciferase reporter gene assay and western blot analysis results. Finally, experiments showed that overexpression of APAF1 suppressed glioma cell growth and promoted cell apoptosis. Conclusions: Our findings characterized the expression properties of miR-23a, contributed to the function and molecular mechanism of miR-23a in glioma and implied that miR-23a might be employed as novel prognostic markers and therapeutic targets of glioma.